Peptides and Muscle: What the Research Actually Shows

TL;DR

• No peptide is FDA-approved for building muscle in healthy adults. The closest approved drug, tesamorelin (Egrifta), is approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
• Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin) raise GH and IGF-1 in short studies. None has a controlled trial measuring muscle size, strength or body composition in healthy people.
• IGF-1 LR3 has no published clinical trials. The only approved IGF-1 drug, mecasermin (Increlex), treats growth failure in children with severe IGF-1 deficiency.
• MOTS-c improved physical capacity in mice. The human data in that work is observational: exercise raises the body's own MOTS-c.
• GLP-1 drugs cause real lean-mass loss alongside fat loss. Across 20 randomized trials, lean mass was roughly a quarter to a third of the weight lost, a proportion similar to diet alone. Resistance training brought it down the most.
• Every compound above is prohibited in sport under the World Anti-Doping Agency (WADA) list, and CJC-1295, ipamorelin and MOTS-c sit on FDA's compounding safety-risk list.

This is an educational guide from PeptIQ.io. It contains no dosing information. Talk with a licensed clinician before starting, stopping or changing any peptide or medication.

How Muscle Grows and Shrinks

Muscle tissue is constantly being built and broken down. You gain muscle when protein synthesis outpaces breakdown for long enough, and you lose it when the balance flips. A few systems control that balance, and every peptide marketed for muscle claims to act on one of them:

• Mechanical tension. Lifting against resistance is the strongest known trigger for muscle protein synthesis. The signal runs through a pathway called mTOR inside the muscle fiber.
• The GH/IGF-1 axis. The pituitary gland releases growth hormone (GH). GH tells the liver to make insulin-like growth factor 1 (IGF-1), and IGF-1 acts on receptors in muscle that feed into the same mTOR pathway.
• Satellite cells. Muscle fibers carry a reserve of stem-like cells that help repair damage and support growth.
• Mitochondria. The energy machinery of the fiber. It does not build muscle directly, but it sets how well muscle performs and recovers.
• Energy balance. In a calorie deficit, including the one a GLP-1 drug creates, the body draws on lean tissue as well as fat.

Growth hormone secretagogues target the first stop on the GH/IGF-1 axis. IGF-1 analogs skip the pituitary and act on the receptor. MOTS-c is a mitochondrial signal. GLP-1 drugs work on appetite, so their muscle effect is a side effect of weight loss. Keep that map in mind; it explains why the evidence differs so much from one compound to the next.

Growth Hormone Secretagogues: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin

"GH secretagogue" covers two families. Growth hormone-releasing hormone (GHRH) analogs, including sermorelin, CJC-1295 and tesamorelin, copy the signal the hypothalamus sends to the pituitary. Ghrelin-receptor agonists, including ipamorelin and the older GHRP compounds, act on a different pituitary receptor. Both end in the same place: more of your own GH, and downstream, more IGF-1.

CJC-1295. The main human data comes from two randomized, placebo-controlled trials in healthy adults published in 2006. A single injection raised mean GH levels two- to ten-fold for six days or more and IGF-1 levels one-and-a-half- to three-fold for nine to eleven days. Those are hormone measurements. The trials did not measure muscle size, strength, or body composition, and they lasted 28 and 49 days. FDA has since placed CJC-1295 in category 2 of its compounding bulk-substances review, citing immunogenicity risk and reports of serious adverse events including increased heart rate and a systemic vasodilatory reaction, with "limited" clinical data. See the CJC-1295 with DAC vs without DAC guide for the pharmacology.

Ipamorelin. Ipamorelin was described in 1998 by Novo Nordisk researchers as the first selective GH secretagogue: in rat and pig studies it released GH without raising cortisol or ACTH. The only randomized human trial we found tested intravenous ipamorelin for postoperative ileus after bowel surgery, not muscle, and found no significant difference from placebo on its efficacy endpoints. FDA's category 2 entry notes a published report of serious adverse events, including death, when ipamorelin was given intravenously for gastric motility, and says the agency lacks safety information for other injectable routes. There is no controlled trial of the popular CJC-1295 and ipamorelin combination as a combination.

Sermorelin. Sermorelin was once an approved drug (Geref). FDA now lists that product as discontinued, and no currently approved sermorelin product exists for muscle or body composition. Read the sermorelin guide.

Tesamorelin. This is the one GH secretagogue with a current FDA label, and the label is narrow: Egrifta is indicated "for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." The label's limitations of use say it is not indicated for weight-loss management (it is weight neutral) and that long-term cardiovascular safety has not been established. In the two 26-week pivotal studies, the label reports a small increase in lean body mass versus a small decrease on placebo, but the trials were designed around visceral fat, in people with HIV, and the drug was never studied as a muscle-building therapy. Most common adverse reactions on the label are joint pain, injection-site redness and itching, pain in the extremities, swelling and muscle pain, and the label tells clinicians to monitor IGF-1 and blood glucose. Our what does tesamorelin do guide covers the trial outcomes in detail.

The pattern across all four: the human evidence is about hormone levels or a specific medical condition. "Raises GH" is not the same claim as "builds muscle," and nobody has run the trial that connects them in healthy adults. The GH/IGF-1 axis review explains why self-reported results muddy that picture.

IGF-1 Analogs: IGF-1 LR3 and Mecasermin

IGF-1 is the hormone that GH secretagogues are ultimately trying to raise. Two products come up in muscle searches:

Mecasermin (Increlex) is recombinant human IGF-1 and an FDA-approved prescription drug. Its indication is growth failure in children two years and older with severe primary IGF-1 deficiency, or with GH gene deletion and neutralizing antibodies to GH. The label states it is not a substitute for GH in GH-approved indications. It is not approved for adults, athletes or body composition.

IGF-1 LR3 is a lab-modified IGF-1 with a changed amino acid at position 3 and an extended chain, designed to bind less to the carrier proteins that normally limit free IGF-1 activity. It is not an approved drug anywhere. A PubMed search for clinical trials of IGF-1 LR3 returns none; the human-tagged literature is lab work and anti-doping detection methods. Everything written about its muscle effect is extrapolated from how IGF-1 itself behaves in cells and animals. Our IGF-1 LR3 guide goes deeper on the pharmacology and the hypoglycemia concern that comes with anything acting on insulin-like receptors.

Mitochondrial Peptides: MOTS-c

MOTS-c is a short peptide encoded in mitochondrial DNA. The 2021 Nature Communications paper that put it on the map reported that MOTS-c treatment improved physical performance in young, middle-aged and old mice, and that late-life treatment increased physical capacity and healthspan. The human part of that paper is observational: exercise raises the body's own MOTS-c in skeletal muscle and in circulation. That is a reason to study it, not evidence that injecting it builds or protects muscle in people.

Regulators have noticed. FDA's category 2 entry for MOTS-c says the agency "has not identified any human exposure data" for compounded MOTS-c products and lacks information on whether it would cause harm. WADA lists MOTS-c under section S4.4 (metabolic modulators, as an AMPK activator), prohibited at all times. For the broader research picture, read MOTS-c and muscle bioenergetics, the mitochondrial peptide research primer, and MOTS-c vs GHK-Cu for muscle over 50.